Compare CLIR & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLIR | LGVN |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 34.0M |
| IPO Year | 2011 | 2021 |
| Metric | CLIR | LGVN |
|---|---|---|
| Price | $4.36 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $3.00 |
| AVG Volume (30 Days) | 16.2K | ★ 383.9K |
| Earning Date | 04-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | $530,000.00 | ★ $709,000.00 |
| Revenue This Year | $34.29 | N/A |
| Revenue Next Year | $67.31 | $10.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.39 | $0.48 |
| 52 Week High | $7.56 | $1.80 |
| Indicator | CLIR | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 44.83 |
| Support Level | $4.18 | $0.74 |
| Resistance Level | $4.75 | $0.86 |
| Average True Range (ATR) | 0.41 | 0.07 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 30.43 | 49.92 |
ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.